16) Tamura S, Imano M, Takiuchi H et al : Phase II study of docetaxel, cisplatin and 5-fluorouracil (DCF) for metastatic esophageal cancer (OGSG 0403). Anticancer Res 32 (4) : 1403-1408, 2012
17) Eisterer W, DE Vries A, Kendler D et al : Triple induction chemotherapy and chemoradiotherapy for locally advanced esophageal cancer. A phase II study. Anticancer Res 31 (12) : 4407-4412, 2011
18) Adelstein DJ, Rodriguez CP, Rybicki LA et al : A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction. Invest New Drugs 30 (4) : 1684-1689, 2012
19) Tomblyn MB, Goldman BH, Thomas CR Jr et al : Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer : a phase-II study of the SWOG (S0414). J Thorac Oncol 7 (5) : 906-912, 2012
20) Schmitt JM, Sommers SR, Fisher W et al : Sunitinib plus paclitaxel in patients with advanced esophageal cancer : a phase II study from the Hoosier Oncology Group. J Thorac Oncol 7 (4) : 760-763, 2012
21) Hurt CN, Nixon LS, Griffiths GO et al : SCOPE1 : a randomised phase II/III multicentre clinical trial of definitive chemoradiation, with or without cetuximab, in carcinoma of the oesophagus. BMC cancer 11 : 466, 2011
22) Yuasa Y, Seike J, Yoshida T et al : Sentinel lymph node biopsy using intraoperative indocyanine green fluorescence imaging navigated with preoperative CT lymphography for superficial esophageal cancer. Ann Surg Oncol 19 (2) : 486-493, 2012
23) Dantoc M, Cox MR, Eslick GD : Evidence to support the use of minimally invasive esophagectomy for esophageal cancer : a meta-analysis. Arch Surg 147 (8) : 768-776, 2012